Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant;Evaluación farmacocinética y farmacodinámica del tratamiento con vancomicina en la bacteriemia por Staphylococcus aureus resistente a meticilina

Revista Espanola de Quimioterapia

Volumn 23, Issue 1, 2010, Pages 43-47

  Lepe, José A ^a,b   Gil Navarro, M Victoria ^a   Santos Rubio, M Dolores ^a   Bautista, Javier ^a   Aznar, Javier ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

AUC MIC; Monte Carlo; MRSA; Pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; DRUG SCREENING; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; SPAIN; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; YOUNG ADULT;

EID: 77956526885     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 (Suppl 1): 35-39
2. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200. (Pubitemid 351269157)
3. Lodise TP, Graves J, Evans A, E. Graffunder,Helmecke M, Lomaestro BM et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-3320
4. Mensa J, Barberán J, Llinares P, Picazo JJ, Bouza E, Álvarez-lerma F et al. Guía de tratamiento de la infección producida por Staphylococcus aureus resistente a meticilina. Rev Esp Quimioter 2008; 21: 234-258
5. Gudiol F, Aguado JM, Pascual A, Pujol M, Almirante B; Miró JM et al. Documento de consenso sobre el tratamiento de la bacteriemia y la endocarditis causada por Staphylococcus aureus resistente a la meticilina. Enferm Infecc Microbiol Clin 2009; 27: 105-115
6. Gould FK, Brindle R, Chadwick PR, Fraise AP, Hill S, Nathwani D et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009; 63: 849-861
7. del Mar Fernández de Gatta, Garcia M, Revilla N, Calvo MV, Domínguez-Gil A, Sánchez Navarro A. Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33: 279-285
8. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947-955
9. Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008; 52: 452-458
10. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.